TrueTear Intranasal Tear Neurostimulator

FDA 510(k) K193589 · Allergan

Substantially Equivalent

510(k) numberK193589

Submission

Device name
TrueTear Intranasal Tear Neurostimulator
Applicant
Allergan
Irvine, CA, US
Received
December 23, 2019
Decision date
August 31, 2020
Decision
Substantially Equivalent (SESE)
Type
Traditional 510(k)
Summary
510(k) summary available from FDA

Official FDA 510(k) record

Device classification

Product code
QBR – Intranasal Electrostimulation Device For Dry Eye Symptoms
Device class
Class II (moderate risk)
Regulation
21 CFR 886.5310
Specialty
Ophthalmic

This device type is intended to temporarily increase tear production using neurostimulation to improve dry eye symptoms. For prescription use only.

More from Allergan

510(k)DeviceDecision
K203229NATRELLE INSPIRA Single Use Sizers for Gel ImplantsMRD · Special 06/02/2021SE
K190674REFRESH RELIEVA For CONTACTSLPN · Traditional 08/08/2019SE
K180826Natrelle 133 Plus MICROCELL Tissue ExpanderLCJ · Traditional 12/21/2018SE
K182054Natrelle 133S Tissue ExpanderLCJ · Special 08/29/2018SE
K161457XEN Glaucoma Treatment SystemKYF · Traditional 11/21/2016SE
K143354Natrelle 133 Plus Tissue ExpanderLCJ · Traditional 08/20/2015SE
K123128Seri Surgical ScaffoldOXF · Traditional 04/25/2013SE
K083812Refresh Optive Lens Comfort Rewetting DropsLPN · Traditional 07/09/2009SE
K051852Single Amplifier for BotoxGWL · Traditional 09/14/2005SE
K014202Complete Brand Multi-Purpose SolutionLPN · Traditional 02/20/2002SE

Questions and answers

When was TrueTear Intranasal Tear Neurostimulator cleared by the FDA?

TrueTear Intranasal Tear Neurostimulator (K193589) received a 510(k) decision of Substantially Equivalent on August 31, 2020, 252 days after the submission was received.

What is the product code of K193589?

The FDA product code is QBR – Intranasal Electrostimulation Device For Dry Eye Symptoms, a Class II (moderate risk) device regulated under 21 CFR 886.5310.